• On October 14, 2026, Rua Bioscience announced a sales and distribution agreement with Curaleaf Laboratories, providing access for its medicinal cannabis products to Curaleaf’s established UK network.
  • This agreement is a clear catalyst for the stock's 11.11% surge to NZD 0.03 today.
  • The deal is expected to generate approximately NZ$10 million in revenue over an initial two-year term, strengthening Rua's European footprint.